The national impact of ritodrine hydrochloride for inhibition of preterm labor.
Article Details
- CitationCopy to clipboard
Leveno KJ, Little BB, Cunningham FG
The national impact of ritodrine hydrochloride for inhibition of preterm labor.
Obstet Gynecol. 1990 Jul;76(1):12-5.
- PubMed ID
- 2359558 [ View in PubMed]
- Abstract
Ritodrine hydrochloride is a beta 2-receptor agonist that relaxes uterine smooth muscle. It was developed specifically for treatment of preterm labor and was approved for this indication in 1980 by the Food and Drug Administration. Estimates of ritodrine usage in the United States were calculated based upon annual sales, and these were examined in relation to the incidence of births in 500-g weight categories less than 2500 g. We estimate that more than 100,000 women with preterm labor are treated with ritodrine annually, but this has had minimal if any impact on the incidence of low birth weight in this country.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Ritodrine Beta-2 adrenergic receptor Protein Humans YesAgonistDetails